Profit finally in sight for gene therapy specialist Oxford Bio – ReutersReutersAfter 20 years of losses, gene therapy specialist Oxford BioMedica is at last close to achieving its first profit thanks to the success of Novartis with a pioneering … Continue reading
Profit finally in sight for gene therapy specialist Oxford BioReutersLONDON (Reuters) – After 20 years of losses, gene therapy specialist Oxford BioMedica is at last close to achieving its first profit thanks to the success of Novartis with a pioneerin… Continue reading
Profit finally in sight for gene therapy specialist Oxford BioReuters UKLONDON, Aug 23 (Reuters) – After 20 years of losses, gene therapy specialist Oxford BioMedica is at last close to achieving its first profit thanks to the success of Novartis with … Continue reading
Profit finally in sight for gene therapy specialist Oxford BioTimes of IndiaMakes key component of pioneering Novartis cancer therapy. * Analysts expect full-year net profit from 2019. By Ben Hirschler. LONDON, Aug 23 (Reuters) – After 20 years of loss… Continue reading
Mesothelioma.comGenetically Coded Gene Therapies Will Help Fight CancerMesothelioma.comGenetically Coded Gene Therapies Will Help Fight Cancer Philadelphia, PA – The expected FDA approval of gene therapy for leukemia will kickstart a radically new type… Continue reading
Mesothelioma.comGenetically Coded Gene Therapies Will Help Fight CancerMesothelioma.comGenetically Coded Gene Therapies Will Help Fight Cancer Philadelphia, PA – The expected FDA approval of gene therapy for leukemia will kickstart a radically new type… Continue reading
|
Immunotherapy May Lead to Cure for Type 1 Diabetes
Specialty Pharmacy Times “Exciting immunotherapy research like this increases the likelihood that one day insulin-producing cells can be protected and preserved,” said Karen Addington, UK chief executive of JDRF, which funded the research. “That would mean people at risk of … |
|
‘Breakthrough’ Leukemia Drug Also Portends ‘Quantum Leap’ In Cost
Coeur d’Alene Press The treatment, CTL019, belongs to a new class of medications called CAR T-cell therapies, which involve harvesting patients’ immune cells and genetically altering them to kill cancer. It’s been tested in patients whose leukemia has relapsed in spite of … |